Traders should monitor the initiation of the NPM-139 Phase 1 trial and data readout by year-end 2026 as key catalysts. The planned Cortigent spin-off or IPO could unlock shareholder value, but execution risk remains.
Price Chart
Executive Summary
Vivani Medical reported its 2025 financial results, showing increased net losses and declining cash, but highlighted significant progress in its biopharmaceutical pipeline, particularly the advancement of its semaglutide implant (NPM-139) into a Phase 1 study by mid-2026. The company also emphasized a solid cash runway into mid-2027 due to recent financings and plans to spin off its neuromodulation subsidiary, Cortigent.
Key Financial Metrics
Key Facts
- Net loss for 2025 was $26.6 million, up from $23.5 million in 2024.
- Cash and equivalents decreased to $16.2 million as of December 31, 2025, from $18.4 million in 2024.
- Raised $41.5 million in gross proceeds from financings in 2025 and early 2026.
- Preclinical data show >20% sham-adjusted weight loss sustained for a full year with a single semaglutide implant administration.
- Phase 1 study for NPM-139 expected to begin mid-2026 with data by end of 2026.
- Cortigent, the neurostimulation subsidiary, filed S-1 amendments in March 2026, advancing plans for a potential spin-off or IPO.
Financial Impact
Increased R&D spending led to a 13% YoY rise in net loss; however, $41.5M in financings extended cash runway to mid-2027.
Risk Factors
- Continued losses and reliance on external financing create execution and dilution risk.
- Clinical development timelines may slip, particularly for NPM-139.
- Spin-off or IPO of Cortigent may not qualify for tax-free treatment or may face market resistance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263430 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 424B5 | $1.25 $1.13 | ▲ +9.60% | ▲ +9.57% | $1.11 (+11.20%) |
Aug 17, 2026 10w ago | 8-K | $1.35 $1.23 | ▼ −8.89% | ▼ −6.91% | $1.11 (−17.78%) |
Jul 16, 2026 14w ago | 8-K | $1.35 $1.34 | ▼ −0.74% | ▼ −4.36% | $1.11 (−17.78%) |
Jul 7, 2026 15w ago | 8-K | $1.35 $1.33 | ▼ −1.48% | ▼ −2.81% | $1.11 (−17.78%) |
Jul 2, 2026 16w ago | Press Release | $1.26 $1.30 | ▲ +3.17% | ▲ +3.59% | $1.11 (−11.90%) |
Jun 30, 2026 16w ago | 8-K | $1.24 $1.30 | ▲ +4.84% | ▲ +5.87% | $1.11 (−10.48%) |
Jun 4, 2026 20w ago | 8-K | $1.28 $1.26 | ▼ −1.56% | ▼ −0.19% | $1.11 (−13.28%) |
Mar 26, 2026 30w ago | Press Release | $1.02 $1.39 | ▲ +36.27% | ▲ +23.53% | $1.11 (+8.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers